- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07681310
GreenArt: Nutrikinetics and Bioavailability Studies
26. Juni 2026 aktualisiert von: Fytexia
Baccharis-type Propolis Extract, GreenArt: Nutrikinetics and Bioavailability Studies
The aim of this study is to investigate phenolic compounds from GreenArt, a baccharis-type propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and metabolic profile over 48h by means of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS).
The study follows a cross-over, double-blind, randomized and placebo control design on 10 healthy subjects.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Intervention / Behandlung
- Nahrungsergänzungsmittel: GreenArt D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Nahrungsergänzungsmittel: GreenArt 4D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Nahrungsergänzungsmittel: Placebo
Studientyp
Interventionell
Einschreibung (Geschätzt)
10
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Julien Cases, PhD
- Telefonnummer: +33467219098
- E-Mail: jcases@biotexia.com
Studienorte
-
-
Murcia
-
Guadalupe, Murcia, Spanien, 30107
- UCAM Universidad Católica San Antonio de Murcia
-
Kontakt:
- Linda H. Chung, PhD
- Telefonnummer: + 34 968 278 611
- E-Mail: lhchung@ucam.edu
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male and female with 40% min. and 60% max. of each sex.
- Aged 25 to 69 years old
- BMI range (18.5 - 29.99)
- In good general health as evidenced by medical history
- Ability to take oral supplementation and be willing to adhere to the regimen
- Agreement to adhere to Lifestyle Considerations (controlled diet) throughout study duration
Exclusion Criteria:
- Current use of any medication or food supplement
- Antibiotic use less than 12 weeks before the study
- Pregnancy or lactation
- Known allergic reactions to components of the supplement, i.e., bee products (specially propolis) and known allergy (general)
- Metabolic disorders or any kind of disease
- Current smoker
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: GreenArt D
This arm receives 150 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt D contains 150 mg of GreenArt
|
|
Experimental: GreenArt 4D
This arm receives 600 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt 4D contains 600 mg of GreenArt
|
|
Placebo-Komparator: Placebo
This arm receives 150 mg of mix carriers of the GreenArt ingredient, a baccharis-type propolis phenolic extract
|
Placebo is composed of the carriers of GreenArt : gum arabic, sucrose and silicon dioxide mix.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in plasma area under the curve (AUC) of phenolic metabolites after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) to 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 24 hour post-ingestion
|
|
Change in plasma maximal concentration (Cmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in plasma time to reach maximal concentration (Tmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids, and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in urine area under the curve (AUC) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) to 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 48 hour post-ingestion
|
|
Change in urine maximal concentration (Cmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are penylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
|
Change in urine time to reach maximal concentration (Tmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Zeitfenster: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juni 2026
Primärer Abschluss (Geschätzt)
1. Juli 2026
Studienabschluss (Geschätzt)
1. Juli 2026
Studienanmeldedaten
Zuerst eingereicht
26. Juni 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. Juni 2026
Zuerst gepostet (Tatsächlich)
2. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
2. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. Juni 2026
Zuletzt verifiziert
1. Juni 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- GREENKBA
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .